Objectives: No licensed vaccines or therapeutic agents for human metapneumovirus (hMPV) infection exist to date. We aimed to construct a multi-epitope peptide (MEP) of hMPV to show promising results for epitope-based vaccine development. Methods: Six independent algorithms were screened to predict B-cell epitopes of hMPV, and three algorithms were used to predict cytotoxic T lymphocyte and T helper (Th) lymphocyte epitopes. Predicted epitopes were assembled in series with the spacers GPGPG and KK introduced, termed MEP. Recombinant mep genes were inserted into pET32a(+) plasmid and expressed in Escherichia coli strain BL21 (DE3). BALB/c mice were immunized with MEP with different adjuvants. Antibody titer, lymphocyte proliferation, cytotoxic T lymphocyte (CTL) activity and splenocyte cytokines were detected 2 weeks later after the last immunization. Microneutralization assay was used to detect neutralizing antibodies. Results: Six B-cell epitopes, four CTL epitopes and two Th epitopes were screened to construct the mep gene. Expressed MEP induced >104 antibodies in BALB/c mice, and produced anti-MEP antibody reacting with hMPV strains specifically as detected in indirect fluorescent assay (the titer was 160). The lymphocyte proliferation index, CTL activity and splenocyte cytokines of the MEP immunization groups were higher than in the control group (p < 0.05). Both IgG1 and IgG2a antibodies could be detected in the different groups, and balanced Th1/Th2 cytokines were secreted by splenocytes in these groups. The mean neutralizing titers of the MEP+CpG ODN, MEP+Alum and MEP+Alum+ CpG ODN groups were 87 (95% CI 50-126), 93 (95% CI 67-121) and 96 (95% CI 69-147), respectively. Conclusion: MEP of hMPV elicited both strong humoral immunity and cell-mediated immunity in mice. The anti-MEP serum could neutralize hMPV infection in vitro. Joint use of CpG ODN and aluminum hydroxide adjuvants obtained the best immune effects. This study may contribute to hMPV epitope-based vaccine development.

Keywords:
Human metapneumovirus, B epitope, Cytotoxic T lymphocyte epitope, T helper epitope, Multi-epitope peptide, Adjuvant
1.
Alonso WJ, Laranjeira BJ, Pereira SA, Florencio CM, Moreno EC, Miller MA, et al: Comparative dynamics, morbidity and mortality burden of pediatric viral respiratory infections in an equatorial city. Pediatr Infect Dis J 2012;31:e9-e14.
2.
Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Côté S, et al: Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002;186:1330-1334.
3.
Pelletier G, Dery P, Abed Y, Boivin G: Respiratory tract reinfections by the new human metapneumovirus in an immunocompromised child. Emerg Infect Dis 2002;8:976-978.
4.
Biacchesi S, Skiadopoulos MH, Boivin G, Hanson CT, Murphy BR, Collins PL, et al: Genetic diversity between human metapneumovirus subgroups. Virology 2003;315:1-9.
5.
van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, et al: A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001;7:719-724.
6.
Li XY, Chen JY, Kong M, Su X, Yi YP, Zou M, et al: Prevalence of human metapneumovirus in hospitalized children with respiratory tract infections in Tianjin, China. Arch Virol 2009;154:1831-1836.
7.
van den Hoogen BG, Herfst S, de Graaf M, Sprong L, van Lavieren R, van Amerongen G, et al: Experimental infection of macaques with human metapneumovirus induces transient protective immunity. J Gen Virol 2007;88:1251-1259.
8.
Walsh EE, Peterson DR, Falsey AR: Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med 2008;168:2489-2496.
9.
Pavlin JA, Hickey AC, Ulbrandt N, Chan YP, Endy TP, Boukhvalova MS, et al: Human metapneumovirus reinfection among children in Thailand determined by ELISA using purified soluble fusion protein. J Infect Dis 2008;198:836-842.
10.
Haas LE, Thijsen SF, van Elden L, Heemstra KA: Human metapneumovirus in adults. Viruses 2013;5:87-110.
11.
Larsen JE, Lund O, Nielsen M: Improved method for predicting linear B-cell epitopes. Immunome Res 2006;2:2.
12.
Saha S, Raghava GP: BcePred: prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties; in Nicosia G, Cutello V, Bentley PJ and Timis J (eds): Artificial Immune Systems, Third International Conference (ICARIS 2004), LNCS 3239. Berlin, Springer, 2004, pp 197-204.
13.
Wang HW, Lin YC, Pai TW, Chang HT: Prediction of B-cell linear epitopes with a combination of support vector machine classification and amino acid propensity identification. J Biomed Biotechnol 2011;2011:432830.
14.
Saha S, Raghava GP: Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins 2006;65:40-48.
15.
Singh H, Ansari HR, Raghava GP: Improved method for linear B-cell epitope prediction using antigen's primary sequence. PLoS One 2013;8:e62216.
16.
Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, et al: NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009;61:1-13.
17.
Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M: NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008;36:W509-W512.
18.
Nielsen M, Lund O: NN-align: an artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 2009;10:296.
19.
Nielsen M, Lundegaard C, Lund O: Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 2007;8:238.
20.
Melendi GA, Zavala F, Buchholz UJ, Boivin G, Collins PL, Kleeberger SR, et al: Mapping and characterization of the primary and anamnestic H-2d-restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus. J Virol 2007;81:11461-11467.
21.
Ding J, Lu Y, Chen Y: Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1. FEMS Immunol Med Microbiol 2000;29:123-127.
22.
Hong W, Xiao S, Zhou R, Fang L, He Q, Wu B, et al: Protection induced by intramuscular immunization with DNA vaccines of pseudorabies in mice, rabbits and piglets. Vaccine 2002;20:1205-1214.
23.
Falsey AR, Formica MA, Walsh EE: Microneutralization assay for the measurement of neutralizing antibodies to human metapneumovirus. J Clin Virol 2009;46:314-317.
24.
Feuillet F, Lina B, Rosa-Calatrava M, Boivin G: Ten years of human metapneumovirus research. J Clin Virol 2012;53:97-105.
25.
Anderson LJ: Respiratory syncytial virus vaccine development. Semin Immunol 2013;25:160-171.
26.
Madhumathi J, Prince PR, Anugraha G, Kiran P, Rao DN, Reddy MV, et al: Identification and characterization of nematode specific protective epitopes of Brugia malayi TRX towards development of synthetic vaccine construct for lymphatic filariasis. Vaccine 2010;28:5038-5048.
27.
Wei JC, Huang YZ, Zhong DK, Kang L, Ishag H, Mao X, et al: Design and evaluation of a multi-epitope peptide against Japanese encephalitis virus infection in BALB/c mice. Biochem Biophys Res Commun 2010;396:787-792.
28.
Li S, Peng L, Zhao W, Zhong H, Zhang F, Yan Z, et al: Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses. Vaccine 2011;29:3695-3702.
29.
Herd KA, Mahalingam S, Mackay IM, Nissen M, Sloots TP, Tindle RW: Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice. J Virol 2006;80:2034-2044.
30.
Herd KA, Nissen MD, Hopkins PM, Sloots TP, Tindle RW: Major histocompatibility complex class I cytotoxic T lymphocyte immunity to human metapneumovirus (hMPV) in individuals with previous hMPV infection and respiratory disease. J Infect Dis 2008;197:584-592.
31.
Rock MT, McKinney BA, Yoder SM, Prudom CE, Wright DW, Crowe JE Jr: Identification of potential human respiratory syncytial virus and metapneumovirus T cell epitopes using computational prediction and MHC binding assays. J Immunol Methods 2011;374:13-17.
32.
Rosa DS, Ribeiro SP, Cunha-Neto E: CD4+ T cell epitope discovery and rational vaccine design. Arch Immunol Ther Exp (Warsz) 2010;58:121-130.
33.
Cardin RD, Brooks JW, Sarawar SR, Doherty PC: Progressive loss of CD8+ T cell-mediated control of a γ-herpesvirus in the absence of CD4+ T cells. J Exp Med 1996;184:863-871.
34.
Löwenadler B, Lycke N, Svanholm C, Svennerholm AM, Krook K, Gidlund M: T and B cell responses to chimeric proteins containing heterologous T helper epitopes inserted at different positions. Mol Immunol 1992;29:1185-1190.
35.
Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA: Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J Immunol 1994;152:549-556.
36.
Skiadopoulos MH, Biacchesi S, Buchholz UJ, Amaro-Carambot E, Surman SR, Collins PL, et al: Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology 2006;345:492-501.
37.
Schuster JE, Cox RG, Hastings AK, Boyd KL, Wadia J, Chen Z, et al: A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus. J Infect Dis 2015;211:216-225.
38.
Yano A, Onozuka A, Asahi-Ozaki Y, Imai S, Hanada N, Miwa Y, et al: An ingenious design for peptide vaccines. Vaccine 2005;23:2322-2326.
39.
Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, Sidney J, et al: A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol 2002;68:5499-5506.
40.
Zeng R, Qi X, Gong W, Mei X, Wei L, Ma C, et al: Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2. Vaccine 2007;25:7422-7428.
41.
Liu L, Wang J, Li B: Research progress of the novel adjuvant CpG ODN (in Chinese). Chin J New Drugs 2014;23:161-170.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.